Dublin, Oct. 29, 2020 (GLOBE NEWSWIRE) -- The "Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of $2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic.
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
- AstraZeneca Plc
- BioCryst Pharmaceuticals Inc.
- Biondvax
- Daiichi Sankyo Company
- F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
- GlaxoSmithKline Plc
- Mylan N.V
- Natco Pharma Limited
- Novartis AG
- Sanofi
- Seqirus
- Teva Pharmaceutical Industries Limited
Key Topics Covered:
1 Introduction
1.1 Industry Definition and Research Scope
1.2 Research Methodology
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter's five Forces Analysis
3 Segmentation of Asia Pacific Market by Product Type
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 Segmentation of Asia Pacific Market by Influenza Type
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 Segmentation of Asia Pacific Market by Administration Route
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 Segmentation of Asia Pacific Market by Distribution Channel
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 Asia-Pacific Market 2019-2030 by Country
7.1 Overview of Asia-Pacific Market
7.2 Japan
7.3 China
7.4 Australia
7.5 India
7.6 South Korea
7.7 Rest of APAC Region
8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
- AstraZeneca Plc
- BioCryst Pharmaceuticals Inc.
- Biondvax
- Daiichi Sankyo Company
- F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
- GlaxoSmithKline Plc
- Mylan N.V
- Natco Pharma Limited
- Novartis AG
- Sanofi
- Seqirus
- Teva Pharmaceutical Industries Limited
9 Investing in Asia Pacific Market: Risk Assessment and Management
9.1 Risk Evaluation of Asia Pacific Market
9.2 Critical Success Factors (CSFs)
For more information about this report visit https://www.researchandmarkets.com/r/u2gnhh
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.